Skip to main content

Table 4 Published studies on the pharmacokinetics of rivaroxaban in patients (mean)

From: Laboratory monitoring of rivaroxaban in Chinese patients with deep venous thrombosis: a preliminary study

PatientsDemographic informationAgeDosageCmax (ng•mL−1)Ctrough (ng•mL− 1)CL/F (L•h− 1)Vd (L)
Undergoing total hip replacement [17]Caucasian27 ~ 9310 mg qd124.6a9.1a7.349.1
Deep venous thrombosis [18]Caucasian18 ~ 9120 mg qd27025.55.6754.4
Non-valvular atrial fibrillation [19]Caucasian51 ~ 9220 mg qd290326.179.7
  1. amedian; −, not published